Glioblastoma: Patterns of recurrence and efficacy of salvage treatments

Canadian Journal of Neurological Sciences

Volumn 38, Issue 4, 2011, Pages 621-625

  Oh, Jiwon ^a   Sahgal, Arjun ^b   Sanghera, Paul ^b   Tsao, May ^b   Davey, Phil ^b   Lam, Kelvin ^a   Symons, Sean ^b   Aviv, Richard ^b   Perry, James ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ETOPOSIDE; LOMUSTINE; PROCARBAZINE; TEMOZOLOMIDE; ALKYLATING AGENT; DACARBAZINE; DRUG DERIVATIVE;

ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; FEMALE; GLIOBLASTOMA; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SALVAGE THERAPY; TREATMENT RESPONSE; AGED; BRAIN TUMOR; COMPUTER ASSISTED TOMOGRAPHY; DISEASE COURSE; KAPLAN MEIER METHOD; METHODOLOGY; MIDDLE AGED; MORTALITY; NUCLEAR MAGNETIC RESONANCE IMAGING; PROPORTIONAL HAZARDS MODEL; RADIOTHERAPY; TUMOR RECURRENCE;

ADULT; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; DACARBAZINE; DISEASE PROGRESSION; FEMALE; GLIOBLASTOMA; HUMANS; KAPLAN-MEIER ESTIMATE; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROPORTIONAL HAZARDS MODELS; RADIOTHERAPY; RETROSPECTIVE STUDIES; SALVAGE THERAPY; TOMOGRAPHY, X-RAY COMPUTED;

EID: 80053320308     PISSN: 03171671     EISSN: None     Source Type: Journal    
DOI: 10.1017/S0317167100012166     Document Type: Article

References (16)

1. Stupp R, Mason WP, Van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987-96.
2. Hochberg FH, Pruitt A. Assumptions in the radiotherapy of glioblastoma. Neurology. 1980;30(9):907-11.
3. Lee SW, Fraass BA, Marsh LH, et al. Patterns of failure following high-dose 3-D conformal radiotherapy for high-grade astrocytomas: a quantitative dosimetric study. Int J Radiat Oncol Biol Phys. 1999;43(1):79-88.
4. Perry JR, Rizek P, Morrison T, Morrison M, Cashman R. Temozolomide rechallenge in recurrent malignant glioma using a continuous temozolomide schedule: the "rescue" approach. Cancer. 2008;113(8):2152-7.
5. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92(3):205-16.
6. Burnet NG, Lynch AG, Jefferies SJ, et al. High grade glioma: imaging combined with pathological grade defines management and predicts prognosis. Radiother Oncol. 2007;85:371-8.
7. Sanghera P, Perry J, Sahgal A, et al. Pseudoprogression following chemoradiotherapy for glioblastoma multiforme. Can J Neurol Sci. 2010;37(1):36-42.
8. van Nifterik KA, van den Berg J, Stalpers LJ, et al. Differential radiosensitizing potential of temozolomide in MGMT promoter methylated glioblastoma multiforme cell lines. Int J Rad Onc Biol Phys. 2007;69(4):1246-53.
9. Chakravarti A, Erkkinen MG, Nestler U, et al. Temozolomidemediated radiation enhancement in glioblastoma: a report on underlying mechanisms. Clin Cancer Res. 2006;12(15):4738-46.
10. WickW, Wick A, Schulz JB, Dichgans J, Rodemann HP, Weller M. Prevention of irradiation-induced glioma cell invasion by temozolomide involves caspase-3-activity and cleavage of focal adhesion kinase. Cancer Res. 2002;62(6):1915-19.
11. Wick W, Stupp R, Beule A, et al. A novel tool to analyze MRI recurrence patterns. Neuro Oncol. 2008;10(6):1019-24.
12. BrandesAA, TosoniA, Franceschi E, et al. Recurrence pattern after temozolomide concomitant with and adjuvant to radiotherapy in newly diagnosed patients with glioblastoma: correlation with MGMT promoter methylation status. J Clin Oncol. 2009;27(8): 1275-9.
13. Milano MT, Okunieff P, Donatello RS, et al. Patterns and timing of recurrence after temozolomide-based chemoradiation for glioblastoma. Int J Radiat Oncol Biol Phys. 2010;78(4):1147-55.
14. Tolcher AW, Gerson SL, Denis L, et al. Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules. Br J Cancer. 2003;88(7):1004-11.
15. Kerbel RS, Kamen BA. The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer. 2004;4(6):423-6.
16. Perry JR, Bélanger K, MasonWP, et al. Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study. J Clin Onc. 2010;28(12):2051-7.